Not for release to US wire services or distribution in the United States

Media Release

19 October 2022

PHARMAXIS ANNOUNCES TWO-TRANCHE PLACEMENT TO RAISE A$10 MILLION

Highlights:

- A$10.0 million two-tranche placement to a small group of international and domestic institutional investors.
- A$30m pro-forma cash balance[1] post raising.
- Funds raised will be used to advance the Company's current clinical study in myelofibrosis, other clinical studies in or close to recruitment in scarring, liver cancer and Parkinson's disease.
- Placement announced in conjunction with positive interim data from Myelofibrosis Phase 2 cancer trial. Refer separate announcement dated 19 October 2022.

Clinical stage biopharmaceutical company Pharmaxis Ltd (ASX: **PXS** or **Company**) today announces that it has received commitments from institutional investors to subscribe for approximately 82.4 million fully paid ordinary shares at A$0.06 per share, to raise approximately A$4.9 million via a placement within the Company's 15% placement capacity under ASX Listing Rule 7.1 (**Tranche 1**).

The Company has also received further commitments from institutional investors for approximately 84.3 million shares at A$0.06 per share, to raise another approximately A$5.1 million (**Tranche 2**) (together with Tranche 1, the **Placement**). Tranche 2 will be subject to shareholder approval at the Company's Annual General Meeting on 29 November 2022.

The funds raised from the Placement will be to advance the current clinical study in myelofibrosis as well as other clinical studies that are open or due to commence shortly in scarring, liver cancer and Parkinson's disease, as well as general working capital purposes and capital raising costs.

The Placement received strong support from a small group of leading international and domestic institutional investors, including both existing substantial shareholders and new investors.

Gary Phillips, Chief Executive Officer commented, "The positive preliminary data from Pharmaxis phase 2 clinical study in myelofibrosis has impressed global clinical experts and has driven interest from the specialist healthcare investors who have participated in this capital raise. I am delighted by the strong support seen from existing substantial shareholders and would also like to welcome our new institutional investors. The company is now well positioned to build on the positive preliminary data from both the ongoing clinical studies in myelofibrosis and skin scarring to deliver full results during 2023."

Morgans Corporate Limited and Bell Potter Securities Ltd are the Joint Lead Managers and Bookrunners to the Placement.

The shares to be issued under the Placement will be issued at a price of $0.06 per share, which is a discount of approximately 23.1% to the last close of $0.078 on Monday 17 October 2022.

Settlement of shares under the Tranche 1 is expected to take place on Tuesday 25 October 2022. Allotment, quotation and trading of the new shares issued under Tranche 1 are expected to take place on Wednesday 26 October 2022.

Settlement of new shares issued under Tranche 2 is expected to take place on Friday 2 December 2022 following the Company's Annual General Meeting on Tuesday 29 November 2022. Allotment, quotation and trading of the new shares issued under Tranche 2 are expected to take place on Monday 5 December 2022.

Shares issued under the Placement will be issued on the same terms and will rank equally with existing shares.

Note 1: Pro-forma cash includes cash of $9m at June 2022, estimated 2022 R&D tax credit of $5 million (expected receipt H2 CY22), Aptar option exercise fee A$7m received August 2022 and capital raising of $10.0 million less offer costs.

#ENDS#

SOURCE: Pharmaxis Ltd, Sydney, Australia

AUTHORISED FOR RELEASE TO ASX BY:
Pharmaxis Ltd Disclosure Committee. Contact: David McGarvey, Chief Financial Officer and Company Secretary: T +61 2 9454 7203, E david.mcgarvey@pharmaxis.com.au

CONTACT:
Media: Felicity Moffatt: T +61 418 677 701, E felicity.moffatt@pharmaxis.com.au
Investor relations: Rudi Michelson (Monsoon Communications) T +61 411 402 737, E rudim@monsoon.com.au

Join the Pharmaxis mailing list here

Follow us:

About Pharmaxis

Pharmaxis Ltd is an Australian clinical stage drug development company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing revenue.

Pharmaxis is developing its drug PXS-5505 for the bone marrow cancer myelofibrosis which causes a build up of scar tissue that leads to loss of production of red and white blood cells and platelets. The US Food and Drug Administration has granted Orphan Drug Designation to PXS-5055 for the treatment of myelofibrosis and permission under an Investigational Drug Application (IND) to progress a phase 1c/2 clinical trial that began recruitment in Q1 2021. PXS-5505 is also being investigated as a potential treatment for other cancers such as liver and pancreatic cancer. The FDA has granted an IND for a phase 1c/2a clinical trial in liver cancer.

Other drug candidates being developed from Pharmaxis' amine oxidase chemistry platform are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; fibrotic scarring from burns and other trauma; and other inflammatory diseases. PXS-4728 is being studied in collaboration with Parkinson's UK as a best in class SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Pharmaxis has developed two products from its proprietary spray drying technology that are manufactured and exported from its Sydney facility; Bronchitol® for cystic fibrosis, which is approved and marketed in the United States, Europe, Russia and Australia; and Aridol® for the assessment of asthma, which is approved and marketed in the United States, Europe, Australia and Asia.

Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia. www.pharmaxis.com.au

Forward-looking statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual

results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.